ESCRS - Supplement: Current and Emerging Treatment Approaches Addess Unmet Needs in Glaucoma Care
ESCRS - Supplement: Current and Emerging Treatment Approaches Addess Unmet Needs in Glaucoma Care
Supplements

Supplement: Current and Emerging Treatment Approaches Addess Unmet Needs in Glaucoma Care

Supplement: Current and Emerging Treatment Approaches Addess Unmet Needs in Glaucoma Care

Sustained-release implants and micro- or minimally invasive glaucoma surgeries (MIGS) are emerging therapies that address key unmet needs in glaucoma treatment. By broadening the spectrum of interventions, these therapies allow glaucoma specialists to consider more measured approaches earlier in disease progression, with a view to delay as well as safeguard the possibility of further invasive surgeries. Drs. Herbert Reitsamer, Andrew Tatham, and Iqbal Ike K. Ahmed discuss how patient compliance impacts glaucoma progression, the role of sustained-release drug delivery and MIGS in alleviating patient treatment burden, the use of MIGS in combination with cataract surgery, and how these therapies can be incorporated into the treatment paradigm.

Tags: glaucoma
Latest Articles
Here Come the Robots

Robotic surgery applications in ophthalmology are expanding. Dermot McGrath reports from Paris.

Read more...

Optimising Long-Term Visual Outcomes for Patients with Neovascular AMD

High compliance of at-home monitoring with AI PHP system. Cheryl Guttman Krader reports from ARVO 2022.

Read more...

Non-Diffractive EDOF IOLs Gaining Ground

Distance and intermediate vision improve with less glare and halos than diffractive alternatives. Howard Larkin reports from the 2022 ASCRS Annual Meeting.

Read more...

Dexamethasone Intracanalicular Insert for Episodic DED

Early clinical trial results suggest 2–3 weeks of sustained and tapering corticosteroid therapy possible. Howard Larkin reports from the 2022 ASCRS Annual Meeting.

Read more...